Technology – Page 4

ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing

1 year ago talkbio0Tagged actinium-225, Authority, BlackRock, cancer pipeline, Gastro-enteropancreatic neuroendocrine tumor, Investments, Isotopes, medical radioisotopes, Munich, Qatar, Radiopharmaceuticals, SLC22A18 gene, Technology, Temasek

ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

FDA Approves Tris Pharma’s Onyda XR, First Liquid Non-Stimulant ADHD Medication for Pediatric Patients ###

1 year ago talkbio0Tagged Approved, Attention deficit hyperactivity disorder, clonidine, Extended Release Suspension, hydrochloride, Liquid medication, LiquiXR, Non-stimulant, Onyda, Pediatric brand name, Svalbard, Technology, Tris Pharma, United States Food and Drug Administration

Tris Pharma, Onyda XR, ADHD, Non-stimulant, Liquid medication, Pediatric patients, FDA approval, Clonidine hydrochloride, Extended-release oral suspension, LiquiXR technology

ExpressionEdits Secures $13M in Seed Funding to Revolutionize Protein Therapies with AI-Driven Intronization Technology

1 year ago talkbio0Tagged Biotechnology, ExpressionEdits, intronization, protein expression, protein therapies, Technology

ExpressionEdits, Protein therapies, AI-driven intronization technology, Seed funding, Biotechnology, Protein expression

Shimadzu Corporation Expands US Presence with Three New R&D Centers for Pharmaceutical Growth

1 year ago talkbio0Tagged business growth, Central, Corporation, Drug Industry, expansion, innovation, Shimadzu, Technology, U.S.

Shimadzu Corporation, R&D centers, US expansion, pharmaceutical industry, business growth, innovation, technology.

NICE Rejects Coverage for AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Enhertu Due to Cost-Effectiveness Concerns

2 years ago talkbio0Tagged AstraZeneca, Cost Effectiveness, Coverage rejection, Daiichi Sankyo, Enhertu, Health Services, National, Malignant neoplasm of breast, Nitroglycerin/Sodium Citrate/Ethanol Solution, Technology

NICE, Enhertu, AstraZeneca, Daiichi Sankyo, Breast cancer, Cost-effectiveness, Coverage rejection, Technology Appraisal, National Health Service (NHS)